Navigation Links
Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest
Date:10/15/2009

brand-name products. These suits nearly tripled from 2002-2003 and doubled from 2006-2007.

"A Paragraph IV lawsuit will likely cost a generic manufacturer $5 to $10 million, compared to at least $800 million required for a brand company to develop a drug and bring it to market," said Graham, who is also a licensed attorney. "And the reward for being the first successful Paragraph IV challenger is substantial -- 180 days during which no other generic-producing company may enter the market and an average potential payoff during those 180 days alone of $60 million. The law is creating incentives to bring challenges on more and different types of drugs."

As the number of patent challenges has increased, the number of new compounds approved annually by the U.S. Food and Drug Administration (FDA) has fallen from an average of 35 in 1996-2001 to 20 in 2002-2007. Without policy intervention, the effective life of key patents will continue to decline, which will further compress the payback period during which brand-name firms can recoup research and development investments, according to the researchers.

"Lawmakers should consider increasing the length of time brand-name drugs are on the market before generic drugs can enter, because the current five-year period is typically insufficient to recoup research and development costs," added Higgins.

Graham and Higgins suggest that exclusivity be extended for first-in-class and high-risk, high-necessity drugs, such as a preventive medicine for Alzheimer's disease or osteoarthritis. In addition, they propose that policy-makers use incentives to encourage private investments in research to complement public research or offer increased exclusivity to curative and preventive drugs. Auctions could allow companies to bid on specific research projects in return for extended data or market exclusivity.

A 2007 report from The National Academies recommended that the United States should at
'/>"/>

Contact: Abby Vogel
avogel@gatech.edu
404-385-3364
Georgia Institute of Technology Research News
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
2. Spectranetics to Appeal Decision in Patent Litigation
3. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
4. Actavis Confirms its Patent Challenge of Kings Avinza(R)
5. PartsSource Awarded US Patent for PartsFinder(TM) Application
6. Barr Confirms Patent Challenge of UROXATRAL(R)
7. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
8. VNUS Medicals Patent Lawsuit Against Laser Competitors to Proceed to Trial
9. Aida Granted Additional Anti-Cancer Patent
10. China Medicines ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province
11. Wiley X Eyewear(R) Announces Successful Resolution of Patent Infringement Litigation Against PanOptx(R), Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest
(Date:9/23/2014)... driving force behind many chronic diseases, especially liver ... caused by conditions such as viral hepatitis or ... Now, scientists at Virginia Commonwealth University Massey Cancer ... preclinical studies that blocking the expression of a ... the development and progression of liver cancer by ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Becker's ... its list of "125 Hospitals and Health Systems ... health systems featured on the list have orthopedic ... earned recognition from several reputable sources. Exceptional orthopedic ... patients, front-line orthopedic research and treat professional athletes. ...
(Date:9/23/2014)... 2014 The "area under the curve of oxygen ... approach to monitoring blood oxygen levels during procedures using ... & Analgesia . , The AUC Desat provides ... lowbut also on the depth, duration, and rate of ... Paul Niklewski, PhD, of University of Cincinnati and colleagues ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
(Date:9/23/2014)... September 23, 2014 Kenall Manufacturing, ... expanded its MedMaster™ M4 product line with a ... the M4 product line – currently available with ... – providing more flexibility when designing lighting for ... MedMaster M4 Series include:, •Three sizes available ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3
... don,t let love interfere with your work, researchers say , ... who found your Valentine at work, here,s good news. , ... negative effect, a new Canadian study finds. , "Most people ... they don,t affect productivity, de-motivate other colleagues or have an ...
... ... Toppers feature 100% Natural Dunlop Latex for an affordable 100% natural latex mattress or ... organic Eco Wool batting, creating an organic latex mattress, free from chemical fire-retardants. ... (PRWEB) February 14, ...
... ... practitioner now seeing patients in the River Walk Medical Arts Building. , ... (PRWEB) February 14, 2010 -- Elias Medical recently ... office is located within the River Walk Medical Arts Building at 9900 Stockdale Highway, adjacent ...
... , LOS ANGELES , ... today by Consumer Watchdog -- Anthem Blue Cross,s announcement today that ... or more should not deter the California Legislature from taking immediate ... Other California health insurers -- including Blue Shield of ...
... Feb. 13 The beauty of budding plants and ... allergy sufferers, though, gardening can be as much a chore as ... cause an onslaught of allergy symptoms, including sneezing, itchy eyes, congestion ... can take a few simple steps to minimize their risk of ...
... Compassion appeared to be contagious in experiment using volunteers ... do a good deed appears to inspire you to do ... , In an experiment, researchers recruited volunteers who watched a ... a clip from "The Oprah Winfrey Show" in which musicians ...
Cached Medicine News:Health News:Office Romance OK With Most Folks 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 3Health News:Elias Medical Announces Move to New Stockdale Highway Practice 2Health News:Anthem Blue Cross's Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action 2Health News:Avoid Allergens to Reap the Rewards of Gardening 2Health News:Avoid Allergens to Reap the Rewards of Gardening 3Health News:Witnessing Uplifting Behavior May Spur Good Deeds 2
(Date:9/22/2014)... Sept. 22, 2014 The western European ... It is largely a replacement market with fewer ... mergers, acquisitions and partnerships are redefining competitive landscape ... research service provides details about revenue forecasts, unit ... trends across the country. The changing landscape makes ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
Breaking Medicine Technology:Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6
... Council,joins organizations and individuals across the country and around ... December 1, 2007. Since 1988,World AIDS Day has provided ... to reinvigorate global, national, regional,and local efforts to stop ... AIDS Day is leadership. Nearly 27,years since it was ...
... Results Also Show Potentially Differentiating Pharmacokinetic ... ... Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the global ... results of a study,showing VYVANSE(TM) (lisdexamfetamine dimesylate), the first ...
Cached Medicine Technology:AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 2Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 3Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 4Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 5Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 6
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: